)

DiaMedica Therapeutics (DMAC) investor relations material
DiaMedica Therapeutics Cantor Global Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Key program updates and clinical data
Successfully manufactured recombinant tissue kallikrein, overcoming challenges faced by others in the field.
Recent phase II data in preeclampsia showed significant blood pressure reductions and no placental transfer of DM199.
Drug demonstrated a 25 mmHg drop in systolic and 13 mmHg in diastolic blood pressure, with a 13% reduction in pulsatility index, indicating improved placental perfusion.
Safety profile was favorable, with no increase in fetal heart rates and no DM199 detected in cord blood.
Early evidence suggests potential for disease modification by improving endothelial health and uterine artery dilation.
Market opportunity and unmet need
Preeclampsia represents a $5+ billion market in the U.S. with 180,000–250,000 cases annually; focus is on the 30,000 early-onset cases before 34 weeks gestation.
Current treatments are limited, often only delaying delivery by about a week, and many antihypertensives are contraindicated in pregnancy.
Every additional day of gestation can significantly reduce neonatal mortality and long-term complications.
Orphan-like pricing is anticipated due to the high unmet need and cost savings from reduced NICU stays and long-term care.
Mechanism of action and differentiation
DM199 is a recombinant tissue kallikrein, distinct from plasma kallikrein, and does not interact with the fibrinolytic or complement systems.
The drug increases blood flow and oxygenation to the placenta, potentially addressing the root cause of preeclampsia.
Similar proteins are used in Asia for stroke and hypertension, but DM199 is a recombinant, purified form.
Next DiaMedica Therapeutics earnings date

Next DiaMedica Therapeutics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage